CClinicalTrials.gg
Not yet recruitingNCT05858723Updated May 15, 2023

Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool

An interventional study of ROAT in Allergic Contact Dermatitis, sponsored by National Allergy Research Center, Denmark. Not yet recruiting. Open to participants aged 18 Years to 110 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by National Allergy Research Center, Denmark · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 9 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 110 Years
Sex
All
01

Study summary

Linalool is currently one of the most used fragrance substances in cosmetic and household products. Previous studies report a high prevalence (5.9-11.7%) of contact allergy to hydroperoxides of linalool (Lin-OOH)1.0% in pet. among patch tested patients. The optimal test concentration of Lin-OOH in patch tests is not known and requires further investigation. It is of great importance to establish the optimal test concentration and elicitation threshold of Lin-OOH to improve diagnosis and prevent development of Allergic Contact Dermatitis (ACD).

We want to mimic real-life exposure to Lin-OOH, by conducting a ROAT (Repeated Open Application Test) study, on 40 adult participants (20 patients with confirmed contact allergy to Lin-OOH, and 20 healthy participants) to low doses of Lin-OOH using a simulated "perfume", during a maximum of 21 days of exposure.

With this knowledge, we aim to:

  1. Establish the optimal patch test concentration to diagnose ACD to Lin-OOH
  2. In case of confirmed contact allergy, examine the threshold value for the development of ACD upon daily exposure to a simulated leave-on cosmetic product
02

Conditions studied

03

In context

Dermatitis

1,435 studies on the registry are indexed under Dermatitis; 131 are open to participants now.

This study's planned enrollment of 40 is below the median of 64 across 1,131 interventional studies indexed under Dermatitis.

Browse Dermatitis studies →

Lead sponsor

National Allergy Research Center, Denmark is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Allergic participants:

  1. Inclusion criteria

    • Positive (at least one reading) or doubtful patch test (at least two readings) result to hydroperoxides of Linalool within the last ten years
    • Aged 18 years or older
    • Received written and verbal information of the study
    • Signed written consent form
  2. Exclusion criteria

    • Active eczema in test areas (volar forearms)
    • Pregnancy or breast feeding
    • Treatment with topical corticosteroids or other immune suppressants on/near test areas within two weeks prior to study start
    • Systemic immune-suppressant treatment within seven days prior to study start
    • UV exposure of test areas within three weeks prior to study start
    • Unable to cooperate or communicate with the investigators

Healthy controls:

  1. Inclusion criteria

    • Aged 18 years or older
    • Received written and verbal information of the study
    • Signed written consent form
  2. Exclusion criteria

    • Known or possible contact allergy to hydroperoxides of Linalool
    • Known contact allergy to other fragrance allergens
    • Active eczema or other known relevant skin diseases
    • Pregnancy or breast feeding
    • Treatment with topical corticosteroids or other immune suppressants on/near test areas within four weeks prior to study start.
    • Systemic immune-suppressant treatment within four weeks prior to study start.
    • UV exposure of test areas within three weeks prior to study start.
    • Participation in other clinical studies within four weeks prior to study start.
    • Unable to cooperate or communicate with the investigators.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Allergic participants

    Diagnostic Test: ROAT

  • Experimental
    Healthy participants

    Diagnostic Test: ROAT

Interventions

  • Diagnostic testROAT

    Repeated Open Application Test

    Also known as: Patch testing and punch biopsies

06

What researchers measure

Primary outcomes

  1. Establish the optimal patch test concentration to diagnose allergic contact dermatitis to hydroperoxides of linalool via a Repeated Open Application Test

    Establish the optimal patch test concentration to diagnose allergic contact dermatitis to hydroperoxides of linalool via Repeated Open Application Test

    Time frame: 6 months

  2. In case of confirmed contact allergy, examine the threshold value for the development of ACD upon daily exposure to a simulated leave-on cosmetic product

    In case of confirmed contact allergy, examine the threshold value for the development of ACD upon daily exposure to a simulated leave-on cosmetic product

    Time frame: 6 months

Secondary outcomes

  1. The Lin-OOH chemicals can penetrate the skin barrier and reside in the local skin tissue

    Chemical analysis of skin punch biopsies from the exposed skin of the patients' lower back: time of flight secondary ion mass spectrometry (ToF-SIMS) analysis of Lin-OOH in the skin.

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05858723
Lead sponsor
National Allergy Research Center, Denmark
Responsible party
Sofia Hedvig Christina Botvid (M.D, Ph.D. fellow, National Allergy Research Center, Denmark) — Principal investigator
First posted
May 15, 2023
Start date
Aug 2023 (estimated)
Primary completion
Jan 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
May 15, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion